Torrent Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Torrent Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 43 Products, $219.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Torrent Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 43 Products, $219.4M Trade | TransData Nexus

Torrent Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $219.4M Total Trade · DGFT Verified

Torrent Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $219.4M across 43 products in 18 therapeutic categories. Based on 5,890 verified export shipments from Indian Customs (DGFT) records, Torrent Pharmaceuticals Limited is the #1 Indian exporter in 3 products including Isosorbide, Dapsone. Top exports include Pantoprazole ($26.0M), Citalopram ($24.3M), Rosuvastatin ($21.1M).

Torrent Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Torrent Pharmaceuticals Limited pharmaceutical export portfolio — 43 products across 18 therapeutic categories. Source: Indian Customs (DGFT).

Who is Torrent Pharmaceuticals Limited? — Company Overview & Market Position

Torrent Pharmaceuticals Limited, established in 1959 as Trinity Laboratories, is a leading Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Renamed Torrent Pharmaceuticals in 1971, the company is part of the Torrent Group, a conglomerate with interests in healthcare and power sectors. Torrent Pharma specializes in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations across various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, diabetology, anti-infective, urology, and pain management.

As of March 2025, Torrent Pharmaceuticals reported a turnover exceeding ₹11,500 crores, reflecting its significant presence in the Indian pharmaceutical market. The company employs over 17,000 individuals globally, underscoring its expansive operations. Torrent Pharma's product portfolio includes over 2,000 product registrations, with a marketing presence in more than 50 countries.

What Does Torrent Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Pantoprazole$26.0M

Product Portfolio — Top 30 by Export Value

Torrent Pharmaceuticals Limited exports 43 pharmaceutical products across 18 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Pantoprazole	Gastrointestinal	$26.0M	662	1.5%	5
2	Citalopram	CNS & Psychiatric	$24.3M	493	6.8%	4
3	Rosuvastatin	Cardiovascular	$21.1M	512	4.6%	7
4	Escitalopram	CNS & Psychiatric	$17.5M	363	6.2%	3
5	Sertraline	CNS & Psychiatric	$13.1M	279	1.9%	6
6	Isosorbide	Cardiovascular	$9.9M	213	18.4%	1
7	Esomeprazole	Gastrointestinal	$9.8M	259	2.2%	6
8	Gliclazide	Advanced Diabetes Medications	$8.7M	300	2.0%	6
9	Sodium	Nutritional Supplements	$8.5M	248	2.4%	12
10	Montelukast	Respiratory	$8.5M	298	3.2%	6
11	Calcium	Vitamins & Supplements	$8.4M	222	0.9%	12
12	Magnesium	Vitamins & Supplements	$5.6M	115	1.6%	8
13	Omeprazole	Gastrointestinal	$5.2M	210	0.8%	13
14	Nystatin	Antifungals	$5.0M	162	8.0%	5
15	Bisoprolol	Cardiovascular	$4.4M	146	4.1%	6
16	Nifedipine	Cardiovascular	$4.1M	126	11.4%	3
17	Amlodipine	Cardiovascular	$4.1M	99	0.0%	15
18	Telmisartan	Cardiovascular	$3.7M	98	0.0%	11
19	Hydrochlorothiazide	Diuretics	$3.1M	110	0.8%	14
20	Leflunomide	Immunosuppressants	$2.9M	58	15.1%	2
21	Ezetimibe	Lipid & Metabolism	$2.7M	91	0.5%	11
22	Simvastatin	Cardiovascular	$2.3M	97	1.9%	10
23	Dapsone	Antimalarial & Antiparasitic	$2.3M	45	7.3%	1
24	Rivaroxaban	Cardiovascular	$2.1M	59	4.0%	7
25	Fluoxetine	CNS & Psychiatric	$1.9M	39	0.8%	5
26	Valsartan	Cardiovascular	$1.5M	65	0.8%	12
27	Fenofibrate	Lipid & Metabolism	$1.4M	41	1.9%	14
28	Apixaban	Cardiovascular	$1.3M	26	0.7%	13
29	Allopurinol	Lipid & Metabolism	$1.2M	31	0.2%	10
30	Carvedilol	Cardiovascular	$1.1M	93	1.1%	13

Torrent Pharmaceuticals Limited exports 43 pharmaceutical products across 18 therapeutic categories with a total export value of $219.4M. The company is the #1 Indian exporter in 3 products: Isosorbide, Dapsone. The top category is Cardiovascular (26.4% of portfolio), followed by CNS & Psychiatric (26.1%), reflecting a diversified portfolio where the top 5 products account for only 46.5% of total value.

Showing top 30 of 43 products. Contact us for complete data.

Torrent Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Torrent Pharmaceuticals operates multiple state-of-the-art manufacturing facilities in India, strategically located to serve both domestic and international markets. These facilities are situated in Indrad, Dahej, Baddi, Sikkim (Unit I & II), Vizag, Pithampur, and Bileshwarpura. Each plant is equipped with advanced technology and adheres to stringent quality standards, ensuring the production of high-quality pharmaceutical formulations. The company's manufacturing capabilities are complemented by a robust research and development infrastructure, enabling the continuous introduction of new products and the enhancement of existing formulations.

3Key Leadership

Torrent Pharmaceuticals is led by a team of experienced professionals committed to the company's vision and mission. Aman Mehta serves as the Managing Director and Whole-Time Director, overseeing the company's strategic direction and operations. Sudhir Menon holds the position of Executive Director of Finance and Chief Financial Officer, responsible for managing the company's financial strategies and operations. Ashish Hajarnish, with a Master of Pharmacy degree, is the Executive Director of Operations, focusing on the efficient management of manufacturing and supply chain processes. Geena V. Malhotra serves as the Chief Technology Officer, leading the company's technological initiatives and innovations. Chintan M. Trivedi is the Company Secretary and Compliance Officer, ensuring adherence to regulatory requirements and corporate governance standards. Jaydip Bhatt holds the position of Vice President of Human Resources, managing talent acquisition and organizational development. Abdullah Salam Said Al Abri is the Chief Customer Service Officer, responsible for enhancing customer satisfaction and service quality.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Torrent Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Torrent Pharmaceuticals has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the United States, the company has secured approvals for various abbreviated new drug applications (ANDAs), enabling it to market generic versions of branded drugs. Torrent Pharma's products are also registered in the European Union and the United Kingdom, adhering to the stringent regulatory standards of these regions. The company's commitment to quality and compliance has facilitated its entry into other regulated markets, including Australia and Japan, where it continues to expand its footprint. Torrent Pharma's adherence to international regulatory standards underscores its dedication to providing high-quality pharmaceutical products globally.

2Emerging Markets

Torrent Pharmaceuticals has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's commitment to quality and affordability has enabled it to establish a strong foothold in these regions. Torrent Pharma's products are registered in over 50 countries, reflecting its widespread global reach. The company's focus on emerging markets aligns with its mission to provide accessible healthcare solutions worldwide.

Geographic Strategy

Torrent Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Torrent Pharmaceuticals has established a robust presence in the United States market through its FDA-approved manufacturing facilities and a portfolio of approved ANDAs. The company's commitment to quality is demonstrated by its successful inspections and the issuance of Establishment Inspection Reports (EIRs) by the FDA. Torrent Pharma's adherence to FDA regulations and standards underscores its dedication to providing high-quality pharmaceutical products to the U.S. market.

2WHO & EU GMP

Torrent Pharmaceuticals' manufacturing facilities comply with Good Manufacturing Practices (GMP) standards, including those set by the World Health Organization (WHO) and the European Union (EU). The company's commitment to quality is reflected in its adherence to these international standards, ensuring the production of safe and effective pharmaceutical products. Torrent Pharma's compliance with WHO and EU GMP standards facilitates its market access and acceptance in various global markets.

3CDSCO & Indian Regulatory

Torrent Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Torrent Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. In the cardiovascular segment, Torrent Pharma competes with companies like Sun Pharmaceutical Industries and Mankind Pharma, which have significant market shares. In the central nervous system segment, competitors include Divi's Laboratories and Ajanta Pharma, both of which offer a range of products in this therapeutic area. Torrent Pharma's focus on niche marketing and its diverse product portfolio provide it with a competitive edge in these segments.

2Key Differentiators

Torrent Pharmaceuticals' key differentiators include its strong presence in niche therapeutic areas such as cardiovascular, central nervous system, and gastrointestinal segments. The company's commitment to quality is demonstrated by its adherence to international manufacturing standards, including WHO and EU GMP. Torrent Pharma's extensive product portfolio, with over 2,000 product registrations, and its marketing presence in more than 50 countries, underscore its global reach and operational scale. These factors collectively contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Torrent Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Torrent Pharmaceuticals has a strong track record in the pharmaceutical industry, with a diverse product portfolio and a significant presence in over 50 countries. The company's export volume and consistency reflect its reliability as a supplier. Torrent Pharma's adherence to international manufacturing standards, including WHO and EU GMP, and its compliance with regulatory requirements in various markets, underscore its commitment to quality and reliability. These factors make Torrent Pharmaceuticals a dependable partner for pharmaceutical supply needs.

2Certifications to Verify

Importers should verify the following certifications when considering Torrent Pharmaceuticals as a supplier:

FDA Approval: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA) and that its products have approved Abbreviated New Drug Applications (ANDAs).

WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practices (GMP) standards.

Frequently Asked Questions — Torrent Pharmaceuticals Limited

How many pharmaceutical products does Torrent Pharmaceuticals Limited export from India?

Torrent Pharmaceuticals Limited exports 43 pharmaceutical products across 18 therapeutic categories. The top exports are Pantoprazole ($26.0M), Citalopram ($24.3M), Rosuvastatin ($21.1M), Escitalopram ($17.5M), Sertraline ($13.1M). Total export value is $219.4M.

What is Torrent Pharmaceuticals Limited's total pharmaceutical export value?

Torrent Pharmaceuticals Limited's total pharmaceutical export value is $219.4M, based on 5,890 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Torrent Pharmaceuticals Limited the #1 Indian exporter?

Torrent Pharmaceuticals Limited is the #1 Indian exporter in 3 products: Isosorbide (18.4% market share), Dapsone (7.3% market share).

What therapeutic categories does Torrent Pharmaceuticals Limited cover?

Torrent Pharmaceuticals Limited exports across 18 therapeutic categories. The largest are Cardiovascular (26.4%, 15 products), CNS & Psychiatric (26.1%, 5 products), Gastrointestinal (18.7%, 3 products).

Get Full Torrent Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.